BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, April 30, 2026
Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 24, 2005

View Archived Issues

Antipsychotic effects of a new 5-HT2C receptor agonist from Pfizer

Read More

Curcumin and its metabolite highlighted as promising agents for neurologic disorders

Read More

JNJ-27291199, an Hdm2:p53 complex inhibitor, potentiates doxorubicin

Read More

NSC-67657: A CEBPalpha activator with antileukemic potential

Read More

Tanabe updates pipeline progress in H1 FY2005

Read More

Oscient files Factive sNDA for five-day treatment of new indications

Read More

Pfizer exercises option to NicOx collaborative compounds

Read More

Myriad Genetics and Abbott extend pharmacogenetics alliance

Read More

First patient enrolled in European phase III trial of Alzhemed

Read More

Large multivalent immunogen vaccine active in melanoma, renal cell carcinoma

Read More

Tocilizumab study results reveal efficacy in arthritis, systemic lupus erythematosus

Read More

Golimumab improves signs and symptoms of refractory rheumatoid arthritis

Read More

Oral cFMS kinase inhibitor GW-2580 inhibits CSF-1 signaling in vivo

Read More

ALK5 inhibition attenuates profibrotic signaling and fibrogenic response

Read More

Flow-induced arterial remodeling modified by cavtratin

Read More

Novartis reports novel CCR1 antagonists with activity in experimental arthritis

Read More

Clevudine demonstrates sustained activity in chronic hepatitis B patients

Read More

Lassa fever vaccine candidate developed

Read More

ENMD-1198 to enter clinical testing in 2006

Read More

Emergent BioSolutions tests single dose oral typhoid vaccine in Vietnam

Read More

Genzyme acquires Cell Genesys' San Diego manufacturing operation

Read More

Phase IIb HCV study to evaluate celgosivir plus Pegetron

Read More

ChemoCentryx seeks clearance to begin clinical studies of CCX-915

Read More

Enrollment begins in phase III Viprinex study for ischemic stroke

Read More

Phase III Oxytrex results in moderate to severe osteoarthritic pain

Read More

Allergan proposes to acquire Inamed

Read More

Xyrem approved to treat excessive daytime sleepiness in narcolepsy patients

Read More

Approvable letter for Vasovist

Read More

Pexelizumab fails to meet primary endpoint threshold for statistical significance

Read More

Recent Merck KGaA patent claims novel anticoagulant agents

Read More

Cardiovascular agents disclosed in recent patent literature

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for April 30, 2026.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for April 28, 2026
  • Chinabio 2026 partnering

    Chinese biotechs gain leverage as partners in dealmaking

    BioWorld
    China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
  • AI generated image for researcher developing antisense oligonucleotides

    Bio Korea 2026 kicks off with spotlight on oligonucleotides

    BioWorld
    Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
  • Roche identifies new TREM2 agonists

    BioWorld Science
    F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have prepared and tested new compounds acting as triggering receptor expressed on myeloid cells 2 (TREM2)...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing